Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

South African Population Immunity and Severe Covid-19 with Omicron Variant

View ORCID ProfileShabir A. Madhi, Gaurav Kwatra, Jonathan E. Myers, Waasila Jassat, Nisha Dhar, Christian K. Mukendi, Amit J. Nana, Lucille Blumberg, Richard Welch, Nicoletta Ngorima-Mabhena, Portia C. Mutevedzi
doi: https://doi.org/10.1101/2021.12.20.21268096
Shabir A. Madhi
1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shabir A. Madhi
  • For correspondence: shabir.madhi@wits@ac.za
Gaurav Kwatra
1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan E. Myers
3Centre for Environmental and Occupational Health Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Waasila Jassat
4National Institute for Communicable Diseases, Johannesburg, South Africa
M.Med.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nisha Dhar
1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian K. Mukendi
1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit J. Nana
1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
B.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucille Blumberg
4National Institute for Communicable Diseases, Johannesburg, South Africa
M.Med.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Welch
4National Institute for Communicable Diseases, Johannesburg, South Africa
B.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicoletta Ngorima-Mabhena
5ResearchLinkMe, Johannesburg, South Africa
M.B.Ch.B.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Portia C. Mutevedzi
1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background We conducted a seroepidemiological survey from October 22 to December 9, 2021, in Gauteng Province, South Africa, to determine SARS-CoV-2 immunoglobulin G (IgG) seroprevalence primarily prior to the fourth wave of coronavirus disease 2019 (Covid-19), in which the B.1.1.529 (Omicron) variant is dominant. We evaluated epidemiological trends in case rates and rates of severe disease through to December 15, 2021, in Gauteng.

Methods We contacted households from a previous seroepidemiological survey conducted from November 2020 to January 2021, plus an additional 10% of households using the same sampling framework. Dry blood spot samples were tested for anti-spike and anti-nucleocapsid protein IgG using quantitative assays on the Luminex platform. Daily case and death data, weekly excess deaths, and weekly hospital admissions were plotted over time.

Results Samples were obtained from 7010 individuals, of whom 1319 (18.8%) had received a Covid-19 vaccine. Overall seroprevalence ranged from 56.2% (95% confidence interval [CI], 52.6 to 59.7) in children aged <12 years to 79.7% (95% CI, 77.6 to 81.5) in individuals aged >50 years. Seropositivity was 6.22-fold more likely in vaccinated (93.1%) vs unvaccinated (68.4%) individuals. Epidemiological data showed SARS-CoV-2 infection rates increased more rapidly than in previous waves but have now plateaued. Rates of hospitalizations and excess deaths did not increase proportionately, remaining relatively low.

Conclusions We demonstrate widespread underlying SARS-CoV-2 seropositivity in Gauteng Province prior to the current Omicron-dominant wave, with epidemiological data showing an uncoupling of hospitalization and death rates from infection rate during Omicron circulation.

Competing Interest Statement

Dr. Madhi reports grants from the Bill & Melinda Gates Foundation during the conduct of the study, grants and personal fees from the Bill & Melinda Gates Foundation, grants from the South African Medical Research Council, grants from Novavax, grants from Pfizer, grants from Minervax, and grants from the European & Developing Countries Clinical Trials Partnership, outside the submitted work. Dr. Kwatra, Dr. Dhar, Mr. Mukendi, Mr. Nana, Dr. Ngorima-Mabhena, and Dr. Mutevedzi report grants from the Bill & Melinda Gates Foundation during the conduct of the study. Mr. Welch shareholdings in Adcock Ingram Holdings Ltd, Aspen Pharmacare Holdings Ltd, Dischem Pharmacies Ltd, Discovery Ltd, and Netcare Ltd, outside the submitted work. Dr. Myers, Dr. Jassat, and Dr. Blumberg have nothing to disclose.

Funding Statement

Funding support for this survey was provided by the Bill & Melinda Gates Foundation (grant number: INV-023514).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Human Research Ethics Committee at the University of the Witewatersrand granted a waiver for ethics approval of the survey, which was being done at the behest of Guateng Department of Health as part of public health surveillance. Neverthless, informed consent was obtained from all indviduals, who were able to decline participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available at www.wits-vida.org; requests for data sharing should be directed to Professor Shabir A. Madhi, email: Shabir.Madhi{at}wits.ac.za

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 21, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
South African Population Immunity and Severe Covid-19 with Omicron Variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
South African Population Immunity and Severe Covid-19 with Omicron Variant
Shabir A. Madhi, Gaurav Kwatra, Jonathan E. Myers, Waasila Jassat, Nisha Dhar, Christian K. Mukendi, Amit J. Nana, Lucille Blumberg, Richard Welch, Nicoletta Ngorima-Mabhena, Portia C. Mutevedzi
medRxiv 2021.12.20.21268096; doi: https://doi.org/10.1101/2021.12.20.21268096
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
South African Population Immunity and Severe Covid-19 with Omicron Variant
Shabir A. Madhi, Gaurav Kwatra, Jonathan E. Myers, Waasila Jassat, Nisha Dhar, Christian K. Mukendi, Amit J. Nana, Lucille Blumberg, Richard Welch, Nicoletta Ngorima-Mabhena, Portia C. Mutevedzi
medRxiv 2021.12.20.21268096; doi: https://doi.org/10.1101/2021.12.20.21268096

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (659)
  • Epidemiology (10799)
  • Forensic Medicine (8)
  • Gastroenterology (590)
  • Genetic and Genomic Medicine (2949)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1928)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (292)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12517)
  • Intensive Care and Critical Care Medicine (691)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2799)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1466)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2640)
  • Public and Global Health (5366)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)